Endocrine UnitDepartment of Internal Medicine I, University Hospital WürzburgComprehensive Heart Failure CenterUniversity of Würzburg, 97080 Würzburg, Germany Endocrine UnitDepartment of Internal Medicine I, University Hospital WürzburgComprehensive Heart Failure CenterUniversity of Würzburg, 97080 Würzburg, Germany
Eur J Endocrinol. 2015 Mar;172(3):R115-24. doi: 10.1530/EJE-14-0824. Epub 2014 Oct 6.
Adrenal crisis is a life-threatening emergency contributing to the excess mortality of patients with adrenal insufficiency. Studies in patients on chronic replacement therapy for adrenal insufficiency have revealed an incidence of 5-10 adrenal crises/100 patient years and suggested a mortality rate from adrenal crisis of 0.5/100 patient years. Patients with adrenal crisis typically present with profoundly impaired well-being, hypotension, nausea and vomiting, and fever responding well to parenteral hydrocortisone administration. Infections are the major precipitating causes of adrenal crisis. Lack of increased cortisol concentrations during infection enhances pro-inflammatory cytokine release and sensitivity to the toxic effects of these cytokines (e.g. tumour necrosis factor alpha). Furthermore, pro-inflammatory cytokines may impair glucocorticoid receptor function aggravating glucocorticoid deficiency. Treatment of adrenal crisis is simple and highly effective consisting of i.v. hydrocortisone (initial bolus of 100 mg followed by 200 mg over 24 h as continuous infusion) and 0.9% saline (1000 ml within the first hour). Prevention of adrenal crisis requires appropriate hydrocortisone dose adjustments to stressful medical procedures (e.g. major surgery) and other stressful events (e.g. infection). Patient education is a key for such dose adjustments but current education concepts are not sufficiently effective. Thus, improved education strategies are needed. Every patient should carry an emergency card and should be provided with an emergency kit for parenteral hydrocortisone self-administration. A hydrocortisone pen would hold a great potential to lower the current barriers to hydrocortisone self-injection. Improved patient education and measures to facilitate parenteral hydrocortisone self-administration in impending crisis are expected to significantly reduce morbidity and mortality from adrenal crisis.
肾上腺危象是一种危及生命的紧急情况,导致肾上腺皮质功能减退症患者的死亡率过高。对接受慢性肾上腺皮质功能减退症替代治疗的患者进行的研究显示,肾上腺危象的发生率为 5-10/100 患者年,并提示肾上腺危象的死亡率为 0.5/100 患者年。患有肾上腺危象的患者通常表现为极度不适、低血压、恶心和呕吐以及发热,对静脉给予氢化可的松反应良好。感染是导致肾上腺危象的主要诱发因素。在感染期间缺乏增加的皮质醇浓度会增强促炎细胞因子的释放,并增加对这些细胞因子(例如肿瘤坏死因子-α)的毒性作用的敏感性。此外,促炎细胞因子可能会损害糖皮质激素受体功能,从而加剧糖皮质激素缺乏症。肾上腺危象的治疗简单且非常有效,包括静脉给予氢化可的松(初始剂量为 100mg,然后在 24 小时内持续输注 200mg)和生理盐水(最初 1 小时内给予 1000ml)。预防肾上腺危象需要适当调整皮质醇剂量以适应有压力的医疗程序(例如大手术)和其他压力事件(例如感染)。患者教育是进行此类剂量调整的关键,但目前的教育概念效果不够理想。因此,需要改进教育策略。每个患者都应携带急救卡,并应提供用于进行静脉内氢化可的松自我给药的急救包。氢化可的松笔可能会降低目前自行注射氢化可的松的障碍,具有很大的潜力。改善患者教育并采取措施促进即将发生的肾上腺危象时的静脉内氢化可的松自我给药,有望显著降低肾上腺危象的发病率和死亡率。